Tacrolimus + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Erectile Dysfunction

Conditions

Erectile Dysfunction, Prostate Cancer

Trial Timeline

Feb 1, 2005 → Nov 1, 2008

NCT ID

NCT00106392

About Tacrolimus + Placebo

Tacrolimus + Placebo is a approved stage product being developed by Astellas Pharma for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00106392. Target conditions include Erectile Dysfunction, Prostate Cancer.

What happened to similar drugs?

11 of 20 similar drugs in Erectile Dysfunction were approved

Approved (11) Terminated (0) Active (9)

🔄tadalafil + placeboEli LillyPhase 3

🔄tadalafilEli LillyPhase 3

✅TadalafilEli LillyApproved

✅tadalafil + placeboEli LillyApproved

✅Tadalafil + Sildenafil CitrateEli LillyApproved

🔄Tadalafil + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01224028	Phase 2	Completed	Nov 1, 2010	Jun 1, 2011	IgA Nephropathy
NCT00347048	Phase 3	Completed	Sep 1, 2006	Apr 1, 2008	Ulcerative Colitis
NCT00319917	Approved	Completed	Apr 1, 2006	Oct 1, 2008	Rheumatoid Arthritis
NCT00309088	Phase 3	Completed	Apr 1, 2006	Jun 1, 2008	Myasthenia Gravis
NCT00106392	Approved	Completed	Feb 1, 2005	Nov 1, 2008	Erectile Dysfunction

Competing Products

20 competing products in Erectile Dysfunction

See all competitors

Product	Company	Stage	Hype Score
tadalafil + placebo	Eli Lilly	Phase 3	40
YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo	Yuhan	Phase 2	35
Mirabegron	Astellas Pharma	Phase 1/2	32
LY2452473 + Tadalafil + LY900010	Eli Lilly	Phase 1	29
tadalafil + placebo	Eli Lilly	Phase 3	40
tadalafil	Eli Lilly	Phase 3	40
LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473)	Eli Lilly	Phase 2	35
Tadalafil	Eli Lilly	Approved	43
tadalafil + placebo	Eli Lilly	Approved	43
Tadalafil + Sildenafil Citrate	Eli Lilly	Approved	43
Tadalafil + Placebo	Eli Lilly	Phase 3	40
Placebo + Tadalafil	Eli Lilly	Approved	43
Tadalafil + Placebo	Eli Lilly	Approved	43
tadalafil	Eli Lilly	Approved	43
Tadalafil + Sildenafil	Eli Lilly	Approved	43
tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)]	Eli Lilly	Phase 3	40
Tadalafil + Placebo	Eli Lilly	Approved	43
Dapoxetine	Johnson & Johnson	Phase 3	40
dapoxetine	Johnson & Johnson	Phase 3	40
Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor)	Johnson & Johnson	Phase 3	40